Formosa Chemicals & Fibre (1326) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
29 May, 2026Executive summary
Report covers consolidated financials for the nine months ended September 30, 2025 and 2024, with a qualified review opinion due to some subsidiaries and equity-method investments not audited independently, representing up to 19% of assets and significant portions of comprehensive income.
The group operates across petrochemicals, plastics, textiles, green energy, and biomedical segments, with extensive related party transactions and global operations.
Financial highlights
Operating revenue for the nine months ended September 30, 2025 was NT$222.0 billion, down 17% year-over-year from NT$267.3 billion.
Net loss attributable to owners for the nine months ended September 30, 2025 was NT$5.5 billion, compared to net income of NT$1.4 billion in the prior year.
Basic loss per share for the nine months ended September 30, 2025 was NT$0.94, versus earnings per share of NT$0.25 for the same period last year.
Gross margin declined to 3% from 4% year-over-year, reflecting lower sales and higher costs.
Cash and cash equivalents at September 30, 2025 were NT$17.8 billion, down from NT$24.4 billion at December 31, 2024.
Outlook and guidance
Management notes adoption of new IFRS standards but does not expect significant impact on financial condition or performance.
No explicit forward-looking guidance provided.
Latest events from Formosa Chemicals & Fibre
- Q1 2024 returned to profit, but large unrealized investment losses led to a comprehensive loss.1326
Q1 202429 May 2026 - Net income fell sharply despite higher revenue, with a NT$33.7 billion comprehensive loss.1326
Q3 202429 May 2026 - Net income surged to NT$3.47B on 14% revenue growth, despite investment losses.1326
Q2 202429 May 2026 - Revenue rose but net income and equity fell sharply due to large unrealized investment losses.1326
Q4 202429 May 2026 - Q1 2025 posted a net loss and revenue decline, with a qualified audit opinion and higher leverage.1326
Q1 202529 May 2026 - H1 2025 saw a net loss, negative EPS, and broad segment underperformance amid market challenges.1326
Q2 202529 May 2026 - 2025 saw a net loss and revenue drop, but a NT$0.60 dividend was approved.1326
Q4 202529 May 2026 - Q1 115 delivered strong profit recovery, improved margins, and robust investment income.1326
Q1 202629 May 2026